Ultragenyx Pharmaceutical (0LIF) Price & Analysis

0 Followers

0LIF Stock Chart & Stats

$25.75

$0.12(0.46%)

At close: Jul 30 4:00 PM EDT

$25.75

$0.12(0.46%)

Day’s Range― - ―

52-Week Range$12.87 - $41.50

Previous CloseN/A

Volume710.00

Average Volume (3M)27.59K

Market Cap

$1.43B

Enterprise Value$4.31K

Total Cash (Recent Filing)$292.00M

Total Debt (Recent Filing)$1.20B

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Nov 04, 2026

EPS Estimate

-0.93

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.84

Shares Outstanding98,588,875

10 Day Avg. Volume27,249

30 Day Avg. Volume27,591

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)-28.35

Price to Sales (P/S)3.37

P/FCF Ratio-4.80

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$28.21

Price Target Upside9.56% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering20

EPS Forecast (FY)-3.97

Revenue Forecast (FY)$758.48M

Bulls Say, Bears Say

Bulls Say

Revenue Scale And Gross MarginsStrong revenue expansion alongside very high gross margins indicates that Ultragenyx’s approved rare-disease medicines can generate substantial economic value as sales scale. This supports reinvestment in commercial infrastructure and clinical programs, while improving operating leverage if expense growth moderates.

FAYUVI Full FDA ApprovalFull approval of FAYUVI expands Ultragenyx’s commercial portfolio with a therapy addressing a progressive and fatal pediatric disease previously lacking an approved treatment. The associated Priority Review Voucher also creates a potential non-dilutive strategic asset for future capital allocation.

Growing Commercial Product BaseRecord quarterly revenue and growth across several marketed therapies show that Ultragenyx is building a broader commercial foundation rather than relying solely on a single launch. Continued patient additions and geographic expansion can provide recurring revenue support over the next several quarters.

Bears Say

Persistent Operating LossesVery large operating losses show that gross profit is currently insufficient to cover research, development, selling and administrative costs. Until the company achieves its targeted profitability plan, earnings remain vulnerable to execution delays and continued dependence on external financial resources.

Cash Burn And Weak Balance SheetSustained cash consumption reduces financial flexibility and can force difficult choices between funding pipeline development, supporting launches and strengthening the balance sheet. Negative equity compounds this pressure, while the business remains reliant on improved cash generation or additional capital sources.

Pipeline Execution RiskThe Angelman setback weakens confidence in a late-stage pipeline asset and may require Ultragenyx to redirect research spending toward other programs. This increases reliance on existing products and recently approved therapies to deliver growth while future clinical outcomes remain uncertain.

Ultragenyx Pharmaceutical News

Ultragenyx price target raised to $20 from $18 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Ultragenyx (RARE) to $20 from $18 and keeps an Equal...

2d ago

RARE

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

Abeona Therapeutics (ABEO) “congratulated” Ultragenyx Pharmaceutical (RARE) on the U.S. Food and Drug Administration, FDA, approval of FAYUVI,...

2d ago

ABEO

RARE

Ultragenyx price target raised to $39 from $37 at Canaccord

Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $39 from $37 and keeps...

2d ago

RARE

Ultragenyx price target raised to $39 from $33 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Ultragenyx (RARE) to $39 from $33 and keeps an Overweight...

2d ago

RARE

Ultragenyx price target raised to $32 from $31 at Citi

Citi raised the firm’s price target on Ultragenyx (RARE) to $32 from $31 and keeps a Buy rating...

2d ago

RARE

Ultragenyx confirms FDA approval of Fayuvi

Ultragenyx (RARE) announced that the U.S. FDA granted standard full approval of Fayuvi, also known as UX111, for...

3d ago

RARE

FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A

The U.S. Food and Drug Administration approved Fayuvi, which it calls “the first treatment for pediatric patients with...

3d ago

RARE

Ultragenyx call volume above normal and directionally bullish

Bullish option flow detected in Ultragenyx (RARE) with 4,365 calls trading, 1.2x expected, and implied vol increasing almost...

4d ago

RARE

Ultragenyx treatment of GNE myopathy granted orphan designation

Ultragenyx (RARE) Pharmaceutical was granted FDA orphan designation for a treatment of GNE myopathy, according to a post...

6d ago

RARE

Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding

Investors poured fresh capital into applied AI and precision biotech this week, with Gimlet Labs raising $300M at...

10d ago

Why Is Ultragenyx Pharmaceutical Stock (RARE) Down Today?

Ultragenyx Pharmaceutical stock fell over 46% on Thursday following a clinical trial update. ...

17d ago

RARE

Ultragenyx: Fayuvi Approval and Stronger Balance Sheet Support Hold Rating Amid Limited Near‑Term Catalysts

William Blair analyst Sami Corwin has maintained their neutral stance on RARE stock, giving a Hold rating on...

2d ago

RARE

Ultragenyx wins FDA approval for FAYUVI gene therapy

Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On September 17, 2026, Ultragenyx Pharmaceutical Inc. announced that...

3d ago

RARE

Red Cat, USA Rare Earth, uniQure, Ultragenyx, Copart Trending

Analysts are intrested in these 5 stocks: ( ($RCAT) ), ( ($USAR) ), ( ($QURE) ), ( ($RARE)...

15d ago

CPRT

QURE

0LIF FAQ

What was Ultragenyx Pharmaceutical’s price range in the past 12 months?

Ultragenyx Pharmaceutical lowest share price was $12.87 and its highest was $41.50 in the past 12 months.

What is Ultragenyx Pharmaceutical’s market cap?

Ultragenyx Pharmaceutical’s market cap is $1.43B.

When is Ultragenyx Pharmaceutical’s upcoming earnings report date?

Ultragenyx Pharmaceutical’s upcoming earnings report date is Nov 04, 2026 which is in 45 days.

How were Ultragenyx Pharmaceutical’s earnings last quarter?

Ultragenyx Pharmaceutical released its earnings results on Aug 04, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$1.218 by $0.318.

Is Ultragenyx Pharmaceutical overvalued?

According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ultragenyx Pharmaceutical pay dividends?

Ultragenyx Pharmaceutical does not currently pay dividends.

What is Ultragenyx Pharmaceutical’s EPS estimate?

Ultragenyx Pharmaceutical’s EPS estimate is -0.93.

How many shares outstanding does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical has 98,588,875 shares outstanding.

What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?

Ultragenyx Pharmaceutical reported an EPS of -$0.9 in its last earnings report, beating expectations of -$1.218. Following the earnings report the stock price went down -2.17%.

Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?

Currently, no hedge funds are holding shares in GB:0LIF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ultragenyx Pharmaceutical Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-3.24%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Ultragenyx Pharmaceutical (0LIF) Earnings & Revenues

Historic Earnings Reports

0LIF Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

Positive overall: the call highlighted record quarterly revenue, broad-based product growth (including Evkeeza +50% YoY), expanding patient counts across multiple geographies, improving cash consumption versus Q1, and clear near-term catalysts (two PDUFAs and a pivotal readout). Management articulated a credible path to profitability in 2027 with expense discipline and potential non-dilutive PRV monetization. Offsetting risks include a sizable operating loss and expense run-rate, reliance on binary regulatory outcomes, an unmet primary outcome for setrusumab requiring possible new trials, and readout/regulatory uncertainty for GTX-102, but these are framed as manageable and addressable within management's plan.View all GB:0LIF earnings summaries

0LIF Stock 12 Month Forecast

Average Price Target

$28.21

▲(9.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","42":"$42","69":"$69","28.5":"$28.5","55.5":"$55.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.210526315789473,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,28.5,42,55.5,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.75,29,32.25,35.5,38.75,42,45.25,48.5,51.75,55,58.25,61.5,64.75,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.75,25.939271255060728,26.128542510121456,26.317813765182187,26.507085020242915,26.696356275303643,26.88562753036437,27.074898785425102,27.26417004048583,27.453441295546558,27.642712550607285,27.831983805668017,28.021255060728745,{"y":28.210526315789473,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.75,25,24.25,23.5,22.75,22,21.25,20.5,19.75,19,18.25,17.5,16.75,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.835,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.992,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.415,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.515,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.89,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.322,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.015,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.815,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.75,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >